Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
about
Novel agents in the treatment of multiple myeloma: a review about the futureMinimal Residual Disease Assessment in the Context of Multiple Myeloma TreatmentEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexitySpotlight on ixazomib: potential in the treatment of multiple myelomaMagic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingTriplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibPharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyExposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.Deacetylase inhibitors: an advance in myeloma therapy?Update on the optimal use of bortezomib in the treatment of multiple myelomaManagement of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Expanding role of lenalidomide in hematologic malignanciesOral proteasome inhibitor with strong preclinical efficacy in myeloma models.Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.Assessing Combinational Drug Efficacy in Cancer Cells by Using Image-based Dynamic Response Analysis.Targeting ubiquitination for cancer therapies.The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisPharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairmentBortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based PharmacokinetThe investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Ixazomib for the treatment of multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.An update in treatment options for multiple myeloma in nontransplant eligible patients.Clinical treatment of newly diagnosed multiple myeloma.New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.Oral ixazomib maintenance therapy in multiple myeloma.New pharmacotherapy options for multiple myeloma.The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.Which therapies will move to the front line for multiple myeloma?Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
P2860
Q26745924-CC1BF6E9-F7ED-4758-9834-EEAB0E9CD066Q26768653-3B67F57D-B9DE-4D15-81C1-0B49FA8A254CQ26771331-A8568CF7-075C-48C2-A0A0-5D64B9D28775Q26774440-376A1FCA-DBC0-4EAE-9E36-6B62772C9D37Q28075816-426BA047-45B2-41D4-9C2F-E70F454CA394Q30238893-8EB98934-55E0-4C5D-865D-A315A28AE7F5Q33425190-0C822059-6C95-40E9-9CC1-74F52FCBA636Q33425607-C96CBC94-2BBB-4D78-BF9A-6D09FF3DEC8EQ33431175-4E19FBD8-A3B4-405C-A399-00A990A15AA8Q33437790-01F8AD8A-B600-4DA4-AB5D-4CA13C8AB86EQ33438321-FCCD7D2A-1F35-4AA5-A421-CC75208CADEBQ33440007-2B5AF54B-5703-4AD2-95B3-CDA50EA898E8Q33441702-6C1BBB63-D14B-4CAC-A094-44F6B84FA791Q33627312-AAEEB4FD-6683-4FCB-8074-09E0B1A56F44Q35592305-FE068515-E11E-47F2-8B82-6A29D35B0E0EQ35969785-53A8ADC4-1804-4CD6-BC53-C3EFBF29B792Q36302859-0686B689-9E2A-49CC-AFE5-2B07BAF3EB47Q36307049-ECDF2364-74E2-4678-ABE2-2C27974AB6ECQ36672941-328675EA-0475-4257-B0ED-BA795079A204Q37158445-BED11A29-D5B0-4A46-B6A9-3021451472CFQ37348913-48041FE1-F57C-4FA9-A51B-9805A9CA26F7Q37375516-704957CF-851F-47AC-9E46-17BFEAA74D51Q37384878-320CD8BC-FF2F-458C-A735-97123E820BD7Q37644930-4B67D372-5191-412D-8525-6DC41F1D3CDDQ37737800-37473EC9-BADF-4542-AD7C-9DDB9F5990FBQ38372360-A122EFA7-A5C9-48D8-97AB-050B8B45CB18Q38400460-22534ADA-5CAF-4D03-AD1D-D2B5F46DD22BQ38413040-0F7814B2-D608-4C24-B221-83C6F8E98DF2Q38542172-343BE315-B8FE-4F61-80C0-0B1DD6270DDEQ38545607-980018D0-078C-47CB-B8A9-DFF9B2BF5BE1Q38561373-449FB1D8-A120-4832-86DE-B77363CB46E3Q38578071-D434FBE6-EAE2-4C8E-8B38-5880C0758677Q38598891-C04067CF-8C3A-4E91-A89D-A0C24B791815Q38627306-2DCCD00E-6EB6-44A7-A2B0-5B109FE06BB1Q38629837-2CCD1AB2-F97D-4140-939E-E6CD5C3FFB31Q38640514-8FFFA256-BE0B-4716-9624-8B1726B9ECF4Q38673764-EF430F90-F341-4B2C-AF4B-CFA4A3696095Q38685108-34CBB075-6E93-40D3-BED5-60B5D253AE62Q38733592-B5E0B3CD-A41B-4A6C-9877-B39221C29C58Q38757067-F5F9DBF5-DD77-4205-836A-911F75640776
P2860
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Safety and tolerability of ixa ...... an open-label phase 1/2 study.
@ast
Safety and tolerability of ixa ...... an open-label phase 1/2 study.
@en
type
label
Safety and tolerability of ixa ...... an open-label phase 1/2 study.
@ast
Safety and tolerability of ixa ...... an open-label phase 1/2 study.
@en
prefLabel
Safety and tolerability of ixa ...... an open-label phase 1/2 study.
@ast
Safety and tolerability of ixa ...... an open-label phase 1/2 study.
@en
P2093
P50
P1433
P1476
Safety and tolerability of ixa ...... an open-label phase 1/2 study.
@en
P2093
A Keith Stewart
Ai-Min Hui
Alessandra Di Bacco
Deborah Berg
Eileen Liao
Jacob P Laubach
Jesus G Berdeja
Jonathan L Kaufman
Jose Estevam
Mehdi Hamadani
P304
P356
10.1016/S1470-2045(14)71125-8
P577
2014-11-14T00:00:00Z